Elevation Oncology IncNASDAQ:ELEV
- LAST PRICE3.6200
- TODAY'S CHANGE (%)-0.0250 (-0.6859%)
- Bid / Lots3.6100/ 1
- Ask / Lots3.9000/ 1
- Open / Previous Close3.6800 / 3.6450
- Day Range
- 52 Week Range
- Volume872,578
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ELEV |
|---|---|---|
| 09:32 ET | 5722 | 3.725 |
| 09:34 ET | 1761 | 3.69 |
| 09:36 ET | 5655 | 3.69 |
| 09:38 ET | 200 | 3.68 |
| 09:39 ET | 1343 | 3.69 |
| 09:41 ET | 1689 | 3.68 |
| 09:43 ET | 100 | 3.68 |
| 09:45 ET | 200 | 3.68 |
| 09:48 ET | 800 | 3.7 |
| 09:50 ET | 233 | 3.69 |
| 09:52 ET | 100 | 3.6908 |
| 09:56 ET | 132 | 3.7 |
| 09:59 ET | 624 | 3.7 |
| 10:01 ET | 1719 | 3.6706 |
| 10:08 ET | 100 | 3.66 |
| 10:12 ET | 397 | 3.6631 |
| 10:14 ET | 300 | 3.68 |
| 10:17 ET | 100 | 3.67 |
| 10:19 ET | 2216 | 3.6373 |
| 10:21 ET | 100 | 3.635 |
| 10:24 ET | 200 | 3.63 |
| 10:28 ET | 720 | 3.62 |
| 10:30 ET | 20259 | 3.71 |
| 10:32 ET | 4100 | 3.71 |
| 10:33 ET | 300 | 3.71 |
| 10:35 ET | 300 | 3.71 |
| 10:37 ET | 500 | 3.7018 |
| 10:39 ET | 391 | 3.71 |
| 10:44 ET | 700 | 3.71 |
| 10:46 ET | 300 | 3.69 |
| 10:48 ET | 1126 | 3.68 |
| 10:51 ET | 271 | 3.6891 |
| 10:53 ET | 1400 | 3.72 |
| 10:57 ET | 1000 | 3.7299 |
| 11:00 ET | 100 | 3.725 |
| 11:04 ET | 28727 | 3.811 |
| 11:06 ET | 3790 | 3.82 |
| 11:08 ET | 1235 | 3.8 |
| 11:09 ET | 15178 | 3.76 |
| 11:11 ET | 200 | 3.72 |
| 11:13 ET | 300 | 3.7 |
| 11:18 ET | 200 | 3.69 |
| 11:20 ET | 400 | 3.69 |
| 11:22 ET | 100 | 3.695 |
| 11:24 ET | 300 | 3.68 |
| 11:26 ET | 16076 | 3.685 |
| 11:27 ET | 1502 | 3.685 |
| 11:29 ET | 6070 | 3.715 |
| 11:31 ET | 1200 | 3.73 |
| 11:33 ET | 300 | 3.725 |
| 11:36 ET | 2398 | 3.73 |
| 11:40 ET | 400 | 3.725 |
| 11:42 ET | 13681 | 3.755 |
| 11:44 ET | 2790 | 3.73 |
| 11:45 ET | 7165 | 3.7 |
| 11:47 ET | 13359 | 3.63 |
| 11:49 ET | 6554 | 3.6499 |
| 11:51 ET | 3252 | 3.64 |
| 11:54 ET | 700 | 3.63 |
| 11:56 ET | 919 | 3.6425 |
| 11:58 ET | 106 | 3.6412 |
| 12:00 ET | 548 | 3.64 |
| 12:03 ET | 617 | 3.64 |
| 12:05 ET | 527 | 3.645 |
| 12:07 ET | 373 | 3.64 |
| 12:09 ET | 692 | 3.645 |
| 12:12 ET | 574 | 3.64 |
| 12:14 ET | 9275 | 3.65 |
| 12:18 ET | 929 | 3.63 |
| 12:20 ET | 200 | 3.63 |
| 12:21 ET | 682 | 3.64 |
| 12:23 ET | 1373 | 3.6365 |
| 12:25 ET | 1102 | 3.63 |
| 12:27 ET | 247 | 3.6327 |
| 12:30 ET | 638 | 3.63 |
| 12:32 ET | 100 | 3.635 |
| 12:34 ET | 2852 | 3.635 |
| 12:36 ET | 100 | 3.635 |
| 12:38 ET | 7759 | 3.63 |
| 12:39 ET | 23463 | 3.6 |
| 12:41 ET | 7121 | 3.58 |
| 12:43 ET | 73221 | 3.63 |
| 12:45 ET | 1162 | 3.645 |
| 12:48 ET | 299 | 3.66 |
| 12:50 ET | 10300 | 3.67 |
| 12:52 ET | 400 | 3.69 |
| 12:54 ET | 200 | 3.7 |
| 12:56 ET | 700 | 3.68 |
| 12:57 ET | 200 | 3.7025 |
| 12:59 ET | 2794 | 3.7292 |
| 01:01 ET | 323 | 3.72 |
| 01:03 ET | 4563 | 3.68 |
| 01:06 ET | 1865 | 3.696 |
| 01:08 ET | 1763 | 3.74 |
| 01:12 ET | 1168 | 3.74 |
| 01:14 ET | 808 | 3.72 |
| 01:17 ET | 400 | 3.725 |
| 01:19 ET | 200 | 3.74 |
| 01:26 ET | 640 | 3.715 |
| 01:28 ET | 200 | 3.73 |
| 01:30 ET | 1500 | 3.73 |
| 01:42 ET | 300 | 3.7 |
| 01:44 ET | 1600 | 3.71 |
| 01:46 ET | 200 | 3.71 |
| 01:50 ET | 1107 | 3.71 |
| 01:51 ET | 1360 | 3.71 |
| 02:02 ET | 100 | 3.71 |
| 02:04 ET | 1600 | 3.71 |
| 02:06 ET | 4430 | 3.67 |
| 02:08 ET | 600 | 3.66 |
| 02:09 ET | 1262 | 3.66 |
| 02:11 ET | 2104 | 3.665 |
| 02:13 ET | 9008 | 3.67 |
| 02:15 ET | 1240 | 3.65 |
| 02:18 ET | 1691 | 3.6568 |
| 02:20 ET | 402 | 3.65 |
| 02:22 ET | 411 | 3.65 |
| 02:24 ET | 712 | 3.66 |
| 02:26 ET | 414 | 3.65 |
| 02:27 ET | 517 | 3.66 |
| 02:29 ET | 1542 | 3.65 |
| 02:31 ET | 415 | 3.65 |
| 02:33 ET | 32819 | 3.66 |
| 02:36 ET | 38759 | 3.65 |
| 02:38 ET | 3921 | 3.66 |
| 02:40 ET | 915 | 3.6501 |
| 02:42 ET | 935 | 3.65 |
| 02:44 ET | 429 | 3.65 |
| 02:45 ET | 7673 | 3.63 |
| 02:47 ET | 1700 | 3.635 |
| 02:49 ET | 2798 | 3.635 |
| 02:51 ET | 1528 | 3.63 |
| 02:54 ET | 400 | 3.63 |
| 02:56 ET | 1091 | 3.6373 |
| 02:58 ET | 10563 | 3.655 |
| 03:00 ET | 3500 | 3.655 |
| 03:02 ET | 1053 | 3.655 |
| 03:03 ET | 1500 | 3.65 |
| 03:05 ET | 8838 | 3.635 |
| 03:07 ET | 1235 | 3.635 |
| 03:09 ET | 6429 | 3.65 |
| 03:12 ET | 4900 | 3.655 |
| 03:14 ET | 3300 | 3.655 |
| 03:16 ET | 3479 | 3.655 |
| 03:18 ET | 6978 | 3.665 |
| 03:20 ET | 11879 | 3.64 |
| 03:21 ET | 1371 | 3.65 |
| 03:23 ET | 2300 | 3.64 |
| 03:25 ET | 1385 | 3.66 |
| 03:27 ET | 105019 | 3.65 |
| 03:30 ET | 12413 | 3.665 |
| 03:32 ET | 13844 | 3.665 |
| 03:34 ET | 3726 | 3.67 |
| 03:36 ET | 17270 | 3.665 |
| 03:38 ET | 7073 | 3.66 |
| 03:39 ET | 2703 | 3.665 |
| 03:41 ET | 8172 | 3.66 |
| 03:43 ET | 2727 | 3.66 |
| 03:45 ET | 22787 | 3.63 |
| 03:48 ET | 2492 | 3.615 |
| 03:50 ET | 10488 | 3.615 |
| 03:52 ET | 13766 | 3.62 |
| 03:54 ET | 8788 | 3.62 |
| 03:56 ET | 14769 | 3.62 |
| 03:57 ET | 7333 | 3.62 |
| 03:59 ET | 16745 | 3.62 |
Apr 9, 2024
DJ Elevation Oncology Price Target Maintained With a $6.00/Share by HC Wainwright & Co., from 6:31AM ET on Tuesday Apr 09, 2024 by Dow Jones
6:31AM ET on Tuesday Apr 09, 2024 by Dow Jones
Apr 8, 2024
Elevation Oncology Presents Preclinical Proof-of-Concept Data for HER3-ADC Program at AACR Annual Meeting 2024, from 4:30PM ET on Monday Apr 08, 2024 by Dow Jones
4:30PM ET on Monday Apr 08, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Elevation Oncology Inc | 177.3M | -2.4x | --- |
Omeros Corp | 177.3M | -1.1x | --- |
Trevi Therapeutics Inc | 175.2M | -9.5x | --- |
Cardiff Oncology Inc | 178.3M | -4.4x | --- |
Outlook Therapeutics Inc | 182.6M | -2.1x | --- |
Kodiak Sciences Inc | 167.2M | -0.7x | --- |
Company Information
Elevation Oncology, Inc. is an oncology company. The Company is focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. Its lead product candidate, EO-3021 is an antibody-drug conjugate (ADC) designed to target Claudin 18.2, which can selectively deliver a cytotoxic payload directly to cancer cells expressing Claudin 18.2. EO-3021 consists of a fully human immunoglobulin G1 (IgG1) mAb that targets Claudin 18.2 and is site-specifically conjugated to the monomethyl auristatin E (MMAE) payload via a cleavable linker with a drug-to-antibody ratio (DAR) of 2. EO-3021 is designed to bind to Claudin 18.2 on the cell surface and is internalized, upon which the linker is cleaved in the lysosome to release the MMAE payload, a potent anti-mitotic agent. Its second program is an ADC designed to target HER3, which is overexpressed across solid tumors.
Contact Information
- Headquarters
- 101 Federal Street, Suite 1900BOSTON, MA, United States 02110
- Phone
- 716-371-1125
- Fax
- 302-697-4597
Executives
- Chairman of the Board
- Steven Elms
- President, Chief Executive Officer, Director
- Joseph Ferra
- Chief Financial Officer
- Tammy Furlong
- Chief Scientific Officer
- David Dornan
- Chief Medical Officer
- Valerie Jansen
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $177.3M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 48.7M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-1.53 |
Book Value | $1.29 |
P/E Ratio | -2.4x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
